[HTML][HTML] Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
…, S Gadgeel, E Esteban, E Felip… - New England journal …, 2018 - Mass Medical Soc
Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
targetable mutations is platinum-based chemotherapy. Among patients with a tumor …
[HTML][HTML] Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
…, PJ Voon, D Planchard, WC Su, JE Gray… - New England journal …, 2018 - Mass Medical Soc
Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …
[HTML][HTML] Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
…, S Hiret, G Ostoros, K Kubota, JE Gray… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer (NSCLC)
have disease progression despite definitive chemoradiotherapy (chemotherapy …
have disease progression despite definitive chemoradiotherapy (chemotherapy …
[HTML][HTML] Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
…, S Hiret, G Ostoros, K Kubota, JE Gray… - … England Journal of …, 2018 - Mass Medical Soc
Background An earlier analysis in this phase 3 trial showed that durvalumab significantly
prolonged progression-free survival, as compared with placebo, among patients with stage III, …
prolonged progression-free survival, as compared with placebo, among patients with stage III, …
[HTML][HTML] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
…, D Planchard, BC Cho, JE Gray… - … England Journal of …, 2020 - Mass Medical Soc
Background Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor of the
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …
epidermal growth factor receptor (EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing …
[HTML][HTML] Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
DR Spigel, C Faivre-Finn, JE Gray… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with
unresectable, stage III non–small-cell lung cancer and no disease progression after …
unresectable, stage III non–small-cell lung cancer and no disease progression after …
Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell …
…, G Speranza, E Esteban, E Felip… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly
improved overall survival (OS) and progression-free survival (PFS) compared with …
improved overall survival (OS) and progression-free survival (PFS) compared with …
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are
established driver mutations in non-small cell lung cancer (NSCLC) 1 , 2 – 3 . Targeted …
established driver mutations in non-small cell lung cancer (NSCLC) 1 , 2 – 3 . Targeted …
[HTML][HTML] Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial
Introduction In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable,
stage III NSCLC without disease progression after concurrent chemoradiotherapy, …
stage III NSCLC without disease progression after concurrent chemoradiotherapy, …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
…, J Vansteenkiste, H Lena, JC Jaime, JE Gray… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …